The potential of intracellular antibodies for therapeutic targeting of protein-misfolding diseases

Trends in Molecular Medicine

Volumn 14, Issue 9, 2008, Pages 373-380

  Cardinale, Alessio ^a   Biocca, Silvia ^b  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; ALPHA SYNUCLEIN ANTIBODY; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-16] ANTIBODY; AMYLOID BETA PROTEIN[1-40] ANTIBODY; AMYLOID BETA PROTEIN[1-42] ANTIBODY; AMYLOID PRECURSOR PROTEIN ANTIBODY; CATIONIC PEPTIDE; HUNTINGTIN; HUNTINGTIN ANTIBODY; IMMUNOLIPOSOME; INTRACELLULAR ANTIBODY; LIPOSOME; MONOCLONAL ANTIBODY; PARVOVIRUS VECTOR; PEPTIDE; POLYMER; PRION PROTEIN; PRION PROTEIN ANTIBODY; PROTEIN ANTIBODY; RECOMBINANT ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SMALL INTERFERING RNA; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ANTIBODY ENGINEERING; ANTIGEN RECOGNITION; ARTICLE; ATOMIC FORCE MICROSCOPY; BLOOD BRAIN BARRIER; CARBOXY TERMINAL SEQUENCE; CELL BASED GENE THERAPY; DOWN REGULATION; ELECTRON MICROSCOPY; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; IMMUNOTHERAPY; LIPOSOMAL GENE DELIVERY SYSTEM; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OCULOPHARYNGEAL MUSCULAR DYSTROPHY; PARKINSON DISEASE; PRION DISEASE; PROTEIN FOLDING; PROTEIN TARGETING; RECOMBINANT DNA TECHNOLOGY; RNA INTERFERENCE; SCRAPIE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTIBODIES; BRAIN DISEASES; HUMANS; INTRACELLULAR SPACE; PROTEIN ENGINEERING; PROTEIN FOLDING;

EID: 50549094090     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2008.07.004     Document Type: Article

References (81)

1. Chiti F., and Dobson C.M. Protein misfolding, functional amyloid and human disease. Annu. Rev. Biochem. 75 (2006) 333-366
2. Cohen F.E., and Kelly J.W. Therapeutic approaches to protein-misfolding diseases. Nature 426 (2003) 905-909
3. Biocca S., et al. Expression and targeting of intracellular antibodies in mammalian cells. EMBO J. 9 (1990) 101-108
4. Biocca S., and Cattaneo A. Intracellular immunization: antibody targeting to subcellular compartments. Trends Cell Biol. 5 (1995) 248-252
5. Cattaneo, A. and Biocca, S., eds (1997) Intracellular antibodies: development and applications. In Biotechnology Intelligence Unit (Landes, R.G., ed.), p. 196, Springer Verlag
6. Lo A.S., et al. Intracellular antibodies (intrabodies) and their therapeutic potential. Handb. Exp. Pharmacol. 181 (2008) 343-373
7. Lener M., et al. Diverting a protein from its cellular location by intracellular antibodies: the case of p21Ras. Eur. J. Biochem. 267 (2000) 1196-1205
8. Jendreyko N., et al. Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 8293-8298
9. Tanaka T., et al. Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS. EMBO J. 26 (2007) 3250-3259
10. Williams B.R., and Zhu Z. Intrabody-based approaches to cancer therapy: status and prospects. Curr. Med. Chem. 13 (2006) 1473-1480
11. Griffin H., et al. Inhibition of papillomavirus protein function in cervical cancer cells by intrabody targeting. J. Mol. Biol. 355 (2006) 360-378
12. Zdoroveac A., et al. Modulation of graft arteriosclerosis in a rat carotid transplantation model. J. Surg. Res. 145 (2008) 161-169
13. Gonzalez-Alegre P., and Paulson H.L. Technology insight: therapeutic RNA interference - how far from the neurology clinic?. Nat. Clin. Pract. Neurol. 3 (2007) 394-404
14. Pfeifer A., et al. Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice. J. Clin. Invest. 116 (2006) 3204-3210
15. Franich N.R., et al. AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease. Mol. Ther. 16 (2008) 947-956
16. Hoppe-Seyler F., et al. Peptide aptamers: specific inhibitors of protein function. Curr. Mol. Med. 4 (2004) 529-538
17. Sc formation. J. Mol. Biol. 371 (2007) 362-373
18. Holliger P., and Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23 (2005) 1126-1136
19. Tanaka T., et al. Single domain intracellular antibodies: a minimal fragment for direct in vivo selection of antigen-specific intrabodies. J. Mol. Biol. 331 (2003) 1109-1120
20. Tanaka T., and Rabbitts T.H. Functional intracellular antibody fragments do not require invariant intra-domain disulfide bonds. J. Mol. Biol. 376 (2008) 749-757
21. Biocca S., et al. Redox state of single chain Fv fragments targeted to the endoplasmic reticulum, cytosol and mitochondria. Biotechnology (N. Y.) 13 (1995) 1110-1115
22. Cardinale A., et al. Aggresome formation by anti-Ras intracellular scFv fragments. The fate of the antigen-antibody complex. Eur. J. Biochem. 268 (2001) 268-277
23. Cardinale A., et al. Evidence for proteasome dysfunction in cytotoxicity mediated by anti-Ras intracellular antibodies. Eur. J. Biochem. 270 (2003) 3389-3397
24. Cardinale A., et al. Intracellular targeting and functional analysis of single-chain Fv fragments in mammalian cells. Methods 34 (2004) 171-178
25. Hoogenboom H.R. Selecting and screening recombinant antibody libraries. Nat. Biotechnol. 23 (2005) 1105-1116
26. Colby D.W., et al. Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display. J. Mol. Biol. 342 (2004) 901-912
27. Hanes J., et al. Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display. Nat. Biotechnol. 18 (2000) 1287-1292
28. Monsellier E., and Bedouelle H. Improving the stability of an antibody variable fragment by a combination of knowledge-based approaches: validation and mechanisms. J. Mol. Biol. 362 (2006) 580-593
29. Philibert P., et al. A focused antibody library for selecting scFvs expressed at high levels in the cytoplasm. BMC Biotechnol. 7 (2007) 81
30. Contreras-Martínez L.M., and DeLisa M.P. Intracellular ribosome display via SecM translation arrest as a selection for antibodies with enhanced cytosolic stability. J. Mol. Biol. 372 (2007) 513-524
31. Visintin M., et al. Selection of antibodies for intracellular function using a two-hybrid in vivo system. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 11723-11728
32. Selkoe D.J. Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behaviour. Behav. Brain Res. 192 (2008) 106-113
33. Simoneau S., et al. In vitro and in vivo neurotoxicity of prion protein oligomers. PLoS Pathog. 3 (2007) e125
34. Danzer K.M., et al. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J. Neurosci. 27 (2007) 9220-9232
35. Glabe C.G., and Kayed R. Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology 66 (2006) S74-S78
36. Necula M., et al. Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J. Biol. Chem. 282 (2007) 10311-10324
37. Gellermann G.P., et al. Aβ-globulomers are formed independently of the fibril pathway. Neurobiol. Dis. 30 (2008) 212-220
38. Kayed R., et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 (2003) 486-489
39. Bucciantini M., et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416 (2002) 507-511
40. Vieira M.N., et al. Soluble oligomers from a non-disease related protein mimic Aβ-induced tau hyperphosphorylation and neurodegeneration. J. Neurochem. 103 (2007) 736-748
41. Emadi S., et al. Isolation of a human single chain antibody fragment against oligomeric α-synuclein that inhibits aggregation and prevents α-synuclein-induced toxicity. J. Mol. Biol. 368 (2007) 1132-1144
42. Shlyakhtenko L.S., et al. Single-molecule selection and recovery of structure-specific antibodies using atomic force microscopy. Nanomedicine 3 (2007) 192-197
43. Marcus W.D., et al. Characterization of an antibody scFv that recognizes fibrillar insulin and β-amyloid using atomic force microscopy. Nanomedicine 4 (2008) 1-7
44. Cardinale A., and Biocca S. Combating protein misfolding and aggregation by intracellular antibodies. Curr. Mol. Med. 8 (2008) 2-11
45. Blennow K., et al. Alzheimer's disease. Lancet 368 (2006) 387-403
46. Paganetti P., et al. β-site specific intrabodies to decrease and prevent generation of Alzheimer's Aβ peptide. J. Cell Biol. 168 (2005) 863-868
47. Prusiner S.B. Prions. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 13363-13383
48. Aguzzi A., et al. Molecular mechanisms of prion pathogenesis. Annu. Rev. Pathol. 3 (2008) 11-40
49. Sc formation. J. Biol. Chem. 280 (2005) 685-694
50. Vetrugno V., et al. KDEL-tagged anti-prion intrabodies impair PrP lysosomal degradation and inhibit scrapie infectivity. Biochem. Biophys. Res. Commun. 338 (2005) 1791-1797
51. Sc formation. J. Neurochem. 101 (2007) 1516-1526
52. Donofrio G., et al. Paracrine inhibition of prion propagation by anti-PrP single-chain Fv miniantibodies. J. Virol. 79 (2005) 8330-8338
53. Walker F.O. Huntington's disease. Lancet 369 (2007) 218-228
54. Borrell-Pagès M., et al. Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies. Cell. Mol. Life Sci. 63 (2006) 2642-2660
55. Khoshnan A., et al. Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 1002-1007
56. Miller T.W., et al. A human single-chain Fv intrabody preferentially targets amino-terminal huntingtin fragments in striatal models of Huntington's disease. Neurobiol. Dis. 19 (2005) 47-56
57. Murphy R.C., and Messer A. A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease. Brain Res. Mol. Brain Res. 121 (2004) 141-145
58. Wolfgang W.J., et al. Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 11563-11568
59. McLear J.A., et al. Combinational approach of intrabody with enhanced Hsp70 expression addresses multiple pathologies in a fly model of Huntington's disease. FASEB J. 22 (2008) 2003-2011
60. Colby D.W., et al. Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 17616-17621
61. Wang C.E., et al. Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin. J. Cell Biol. 181 (2008) 803-816
62. Wood-Kaczmar A., et al. Understanding the molecular causes of Parkinson's disease. Trends Mol. Med. 12 (2006) 521-528
63. Zhou C., et al. A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed α-synuclein. Mol. Ther. 10 (2004) 1023-1031
64. Abu-Baker A., and Rouleau G.A. Oculopharyngeal muscular dystrophy: recent advances in the understanding of the molecular pathogenic mechanisms and treatment strategies. Biochim. Biophys. Acta 1772 (2007) 173-185
65. Fan X., et al. Oligomerization of polyalanine expanded PABPN1 facilitates nuclear protein aggregation that is associated with cell death. Hum. Mol. Genet. 10 (2001) 2341-2351
66. Verheesen P., et al. Prevention of oculopharyngeal muscular dystrophy-associated aggregation of nuclear polyA-binding protein with a single-domain intracellular antibody. Hum. Mol. Genet. 15 (2006) 105-111
67. Zlokovic B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57 (2008) 178-201
68. Fukuchi K., et al. Anti-Aβ single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. Neurobiol. Dis. 23 (2006) 502-511
69. Levites Y., et al. Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid β, amyloid β40, and amyloid β42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J. Neurosci. 26 (2006) 11923-11928
70. Wuertzer C.A., et al. CNS delivery of vectored prion-specific single-chain antibodies delays disease onset. Mol. Ther. 16 (2008) 481-486
71. Wang Y.J., et al. Intramuscular delivery of a single chain antibody gene reduces brain Aβ burden in a mouse model of Alzheimer's disease. Neurobiol. Aging (2007). http://www.sciencedirect.com/science/journal/01974580 10.1016/j.neurobiolaging.2007.06.013
72. Brantly M.L., et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. Hum. Gene Ther. 17 (2006) 1177-1186
73. Draghia R., et al. Gene delivery into the central nervous system by nasal instillation in rats. Gene Ther. 2 (1995) 418-423
74. Frenkel D., and Solomon B. Filamentous phage as vector-mediated antibody delivery to the brain. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 5675-5679
75. Mueller C., and Flotte T.R. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther. 15 (2008) 858-863
76. Lieber A. AAV display-homing in on the target. Nat. Biotechnol. 21 (2003) 1011-1013
77. Larocca D., et al. Evolving phage vectors for cell targeted gene delivery. Curr. Pharm. Biotechnol. 3 (2002) 45-57
78. Dietz G.P., and Bähr M. Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol. Cell. Neurosci. 27 (2004) 85-131
79. Joliot A., and Prochiantz A. Transduction peptides: from technology to physiology. Nat. Cell Biol. 6 (2004) 189-196
80. Chauhan A., et al. The taming of the cell penetrating domain of the HIV Tat: myths and realities. J. Control. Release 117 (2007) 148-162
81. Popiel H.A., et al. Protein transduction domain-mediated delivery of QBP1 suppresses polyglutamine-induced neurodegeneration in vivo. Mol. Ther. 15 (2007) 303-309